On the stock market since 2002, it operates in the world of health and science. It has 82,878 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year).
The gap is $11.9B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 26% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.
It pays out $2.42 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, SNY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SNY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.